Workflow
司太立(603520) - 2021 Q4 - 年度财报
StarryStarry(SH:603520)2022-04-25 16:00

Financial Performance - In 2021, the company's operating revenue reached ¥1,999,916,888.19, representing a 46.29% increase compared to ¥1,367,087,241.13 in 2020[17] - The net profit attributable to shareholders was ¥323,754,754.88, a 35.62% increase from ¥238,729,340.15 in the previous year[17] - The net profit after deducting non-recurring gains and losses was ¥307,864,117.27, up 30.04% from ¥236,753,234.90 in 2020[17] - The net cash flow from operating activities was ¥508,839,385.25, a significant increase of 191.63% compared to ¥174,479,180.11 in 2020[17] - As of the end of 2021, the total assets amounted to ¥4,895,377,815.83, reflecting an 11.10% increase from ¥4,406,335,461.47 at the end of 2020[17] - The net assets attributable to shareholders increased to ¥2,174,978,008.51, a 19.27% rise from ¥1,823,503,185.33 in 2020[17] - The basic and diluted earnings per share were both 1.32 RMB, reflecting a 32% increase from the previous year[18] - The weighted average return on equity decreased to 16.04%, down 1.67 percentage points from the previous year[18] R&D and Innovation - The company’s R&D expenses increased by 41.82% to CNY 124,580,729.29, reflecting a commitment to innovation[43] - A total of 69 patents have been granted or are under review, including 49 invention patents, indicating a strong focus on innovation[31] - The company submitted supplementary materials for iodinated contrast agents and registered applications for gadobutrol injection, continuing its R&D efforts in the contrast agent field[30] - The company is expanding its product line to include second-generation iodine contrast agents and is actively developing MRI and ultrasound contrast agents[40] - The company’s iodinated contrast agent, Iohexol injection, is currently in the registration review stage[81] - The company’s Gadobutrol injection is also in the registration review stage, indicating ongoing product development[81] Market and Sales Strategy - The company successfully participated in the national fifth batch of centralized drug procurement, enhancing its sales network across provinces[29] - The company has established long-term partnerships with major pharmaceutical companies in China, ensuring stable sales channels[36] - The company’s sales network has been improved across all provinces in China, with a focus on building a professional sales team[36] - The company’s participation in centralized drug procurement has positively impacted sales revenue and market share[78] - The company’s products are included in the National Medical Insurance Directory, ensuring broader market access[76] Corporate Governance and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm[5] - The board of directors has ensured the authenticity and completeness of the annual report, with no false records or misleading statements[5] - The company has implemented a robust corporate governance structure to ensure the protection of shareholder rights and compliance with legal regulations[105] - The company has conducted three shareholder meetings during the reporting period, adhering to all legal and regulatory requirements[108] - The company actively engages with investors through various communication channels to ensure transparency and timely responses to inquiries[107] Environmental Management - The company has committed to enhancing its environmental management practices and compliance with national and local regulations[157] - The company has established a comprehensive environmental risk emergency response mechanism to address potential environmental incidents[162] - The company has improved its wastewater treatment capabilities through upgrades and the construction of a new wastewater treatment plant[163] - The company operates a RTO incineration system with a processing capacity of 15,000 standard cubic meters per hour, ensuring effective waste gas treatment[161] - The company faced an administrative penalty of RMB 330,000 due to exceeding the ammonia nitrogen limit of 54.6 mg/L, which is above the regulatory threshold[156] Employee and Management Structure - The company has reserved 155,600 restricted stocks for 44 incentive targets as part of its employee stock ownership plan, enhancing employee motivation and internal cohesion[30] - The company has a total of 94,403,200 shares held by its directors and supervisors at the end of the reporting period[111] - The company has implemented a salary and welfare management policy, which includes a time-based and piece-rate salary system[132] - The company has a training plan that includes external training and internal training sessions for employees[133] - The company has established a performance evaluation mechanism for senior management, linking their compensation to safety, environmental protection, and overall effectiveness[139] Financial Management and Investments - The company has approved the use of up to 300 million RMB of idle raised funds for cash management, ensuring the safety of the funds[190] - The company has engaged in bank wealth management with a total amount of 80 million RMB from idle raised funds, with no overdue amounts[189] - The total amount of structured deposits collected by the Bank of China reached 3,550 million with an interest rate of 3.50%[192] - The company has made structured deposits with China Bank and CITIC Bank, with expected annualized returns of 1.50% and 2.90% respectively[191] - The total guarantee amount (including guarantees to subsidiaries) is 685,516,361.36 RMB, accounting for 31.52% of the company's net assets[187]